JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 245 productos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JAK-IN-31
CAS:<p>JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,</p>Fórmula:C21H19N7O2S2Pureza:98%Forma y color:SolidPeso molecular:465.55JAK-IN-3
CAS:<p>JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.</p>Fórmula:C18H20N4O3Pureza:98.04% - 98.19%Forma y color:SolidPeso molecular:340.38JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Fórmula:C16H13IN6Forma y color:SolidPeso molecular:416.22JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Forma y color:SolidJAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SForma y color:SolidPeso molecular:599.62Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Fórmula:C24H25N7O2Forma y color:SolidPeso molecular:443.50GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Fórmula:C20H18F2N6O5SForma y color:SolidPeso molecular:492.46YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Fórmula:C19H19F2N7O3Forma y color:SolidPeso molecular:431.40JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Fórmula:C23H22Cl2N4OForma y color:SolidPeso molecular:441.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Fórmula:C18H20F6N4OForma y color:SolidPeso molecular:422.37CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Fórmula:C18H18N4Forma y color:SolidPeso molecular:290.36TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Forma y color:SolidPeso molecular:489.458iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Fórmula:C19H15F3N2O2Forma y color:SolidPeso molecular:360.33AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H14FN5OForma y color:SolidPeso molecular:323.32Tyk2-IN-3
CAS:<p>Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).</p>Fórmula:C25H24N6O3S2Pureza:98%Forma y color:SolidPeso molecular:520.63(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Forma y color:SolidPeso molecular:566.63(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Fórmula:C20H27ClN6OForma y color:SolidPeso molecular:402.92JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Fórmula:C20H15ClF3N3OSForma y color:SolidPeso molecular:437.87
